CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

B-cell tumor development in Tet2-deficient mice

Mouly, Enguerran, Ghamlouch, Hussein, Della-Valle, Veronique, Scourzic, Laurianne, Quivoron, Cyril, Roos-Weil, Damien, Pawlikowska, Patrycja, Saada, Véronique, Diop, M’Boyba K., Lopez, Cécile K., Fontenay, Michaela, Dessen, Philippe, Touw, Ivo P., Mercher, Thomas, Aoufouchi, Said, Bernard, Olivier A.·2018·Blood Advances
DOI 10.1182/bloodadvances.2017014118
Open this paper in CoChat — free account

Abstract

Key Points: Tet2 is a tumor suppressor in B cells. Loss of Tet2 in B cells leads to age-dependent transformation that requires AID.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2017014118

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Tet2 deficiency leads to the accumulation of clonal B220 low B-cell population in a cell-autonomous fashion. (A) Monthly monitoring of blood cell count in Tet2 CD19-Cre 2 and Tet2 CD19-Cre 1 mice. *** P , .001. (B) Monthly monitoring of CD19 1 B220 low abnormal cell population in the blood of Tet2 CD19-Cre 2 and Tet2 CD19-Cre 1 mice (left panel). Significance was tested using an unpaired Student t test. Time-dependent representation of the proportion of the B220 low population within the circulating B cells (CD19 1 ) in the same mice as in panel A (right panel). Significance was tested using an unpaired Student t test. (C) Spleen weight of sacrificed mice at various time points was measured for both types of mice. Significance was tested using an unpaired Student t test. (D) Immunostaining of total splenocytes (polychromatic dot plot) from a representative sick Tet2 CD19-Cre 1 mouse (same genotypes as above). Splenocytes were first stained with B220 and CD19 to define the B220 1 and B220 low population of CD19 1 cells (left polychromatic dot plot). Other dot plots show B220 expression together with the indicated antibody on the x-axis of the overlaid B220 1 CD19 1 population (green) and B220 low CD19 1 population (violet). (E) Analyses of BCR rearrangement clonality in abnormal Tet2 CD19-Cre 1 B cells. V-J junctions were PCR-amplified from cDNA of sorted B cells using VH family primers (VH1, VH2, VH3, VH5, VH6, and VH7, as indicated) and conjugated consensus JH primer 22 to assess the IgH CDR3 diversity. Top panels show Results shown are obtained from sorted Tet2 CD19Cre 2 B splenocytes (B220 1 CD19 1 ) (top) and from age-matched Tet2 CD19-Cre 1 sorted abnormal B cells (B220 low CD19 1 ) (bottom). (F) Transcription of selected genes important for B-cell differentiation differs between normal WT and Tet2 -deficient tumor B cells. Histograms show quantitative reverse transcription (qRT) -PCR analysis results DD CT-normalized by Abl1 expression levels. Results are an average of 3 independent duplicate experiments. The differences were validated in an extension cohort for 8 of the 11 genes. Significance was tested using the Mann-Whitney U test. * P , .05; ** P , .01; *** P , .001. ns, not significant.
Figure 1 Tet2 deficiency leads to the accumulation of clonal B220 low B-cell population in a cell-autonomous fashion. (A) Monthly monitoring of blood cell count in Tet2 CD19-Cre 2 and Tet2 CD19-Cre 1 mice. *** P , .001. (B) Monthly monitoring of CD19 1 B220 low abnormal cell population in the blood of Tet2 CD19-Cre 2 and Tet2 CD19-Cre 1 mice (left panel). Significance was tested using an unpaired Student t test. Time-dependent representation of the proportion of the B220 low population within the circulating B cells (CD19 1 ) in the same mice as in panel A (right panel). Significance was tested using an unpaired Student t test. (C) Spleen weight of sacrificed mice at various time points was measured for both types of mice. Significance was tested using an unpaired Student t test. (D) Immunostaining of total splenocytes (polychromatic dot plot) from a representative sick Tet2 CD19-Cre 1 mouse (same genotypes as above). Splenocytes were first stained with B220 and CD19 to define the B220 1 and B220 low population of CD19 1 cells (left polychromatic dot plot). Other dot plots show B220 expression together with the indicated antibody on the x-axis of the overlaid B220 1 CD19 1 population (green) and B220 low CD19 1 population (violet). (E) Analyses of BCR rearrangement clonality in abnormal Tet2 CD19-Cre 1 B cells. V-J junctions were PCR-amplified from cDNA of sorted B cells using VH family primers (VH1, VH2, VH3, VH5, VH6, and VH7, as indicated) and conjugated consensus JH primer 22 to assess the IgH CDR3 diversity. Top panels show Results shown are obtained from sorted Tet2 CD19Cre 2 B splenocytes (B220 1 CD19 1 ) (top) and from age-matched Tet2 CD19-Cre 1 sorted abnormal B cells (B220 low CD19 1 ) (bottom). (F) Transcription of selected genes important for B-cell differentiation differs between normal WT and Tet2 -deficient tumor B cells. Histograms show quantitative reverse transcription (qRT) -PCR analysis results DD CT-normalized by Abl1 expression levels. Results are an average of 3 independent duplicate experiments. The differences were validated in an extension cohort for 8 of the 11 genes. Significance was tested using the Mann-Whitney U test. * P , .05; ** P , .01; *** P , .001. ns, not significant.CC-BY-NC-ND · From the PDF
Figure 2 Normal steady-state early B-cell development in Tet2 -deficent mice. (A) qRT-PCR analysis transcription levels of the 3 murine Tet genes normalized by Abl1 expression. Results are the average of 3 independent experiments performed in duplicate. (B) Bone marrow B-cell development analysis. Total BM cells were analyzed for B220 and IgM expression. Immature B cells B220 low IgM 1 and mature B cells B220 1 IgM 1 are indicated. Then CD43 expression was evaluated in gated B220 1 IgM 2 cells to define pre-B (CD43 2 ) and pro-B (CD43 1 ) populations; finally, the more immature Hardy fractions (Fr.A CD24 2 Bp1 2 ; Fr.B: CD24 1 Bp1 2 ; and Fr.CC 9 : CD24 1 Bp1 1 ) were analyzed in the pro-B-cell gate. The genotypes of the analyzed mice are indicated on the left side. (C) Average percentage of cell populations. (Left) Total B220 1 cells (each dot represents an independent mouse). (Middle) Average percentage of the indicated population in the B-cell compartment for each genotype. (Right) Hardy fraction percentage inside the pro-B-cell compartment. Genotypes are indicated ( Tet2 1 / 1 mice, n 5 6; Tet2 2 / 2 mice, n 5 8). Im-B, immature B cells B220 low IgM 1 ; Mat-B, mature B cells B220 1 IgM 1 .
Figure 2 Normal steady-state early B-cell development in Tet2 -deficent mice. (A) qRT-PCR analysis transcription levels of the 3 murine Tet genes normalized by Abl1 expression. Results are the average of 3 independent experiments performed in duplicate. (B) Bone marrow B-cell development analysis. Total BM cells were analyzed for B220 and IgM expression. Immature B cells B220 low IgM 1 and mature B cells B220 1 IgM 1 are indicated. Then CD43 expression was evaluated in gated B220 1 IgM 2 cells to define pre-B (CD43 2 ) and pro-B (CD43 1 ) populations; finally, the more immature Hardy fractions (Fr.A CD24 2 Bp1 2 ; Fr.B: CD24 1 Bp1 2 ; and Fr.CC 9 : CD24 1 Bp1 1 ) were analyzed in the pro-B-cell gate. The genotypes of the analyzed mice are indicated on the left side. (C) Average percentage of cell populations. (Left) Total B220 1 cells (each dot represents an independent mouse). (Middle) Average percentage of the indicated population in the B-cell compartment for each genotype. (Right) Hardy fraction percentage inside the pro-B-cell compartment. Genotypes are indicated ( Tet2 1 / 1 mice, n 5 6; Tet2 2 / 2 mice, n 5 8). Im-B, immature B cells B220 low IgM 1 ; Mat-B, mature B cells B220 1 IgM 1 .CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
Figure 4 Tet2-deficient abnormal B cells share features with human B-cell
Figure 4 Tet2-deficient abnormal B cells share features with human B-cellCC-BY-NC-ND · From the PDF
Figure 5 Tet2 -deficient abnormal B-cells are BCR-inhibition sensitive. (A) Abnormal B-cell phenotype and frequencies in the peripheral blood of mice transplanted with TCL1A transduced Tet2 1 / 1 or Tet2 2 / 2 hematopoietic progenitors. Dot plots show a representative example of B220 and CD19 expression analysis in the GFP 1 total leukocytes 4 months after transplantation. Diagrams depict the average percentages of the B220 low population in the blood of n 5 3 mice per group 4 months after transplantation. Error bars represent means 6 standard deviation (SD). (B) Tet2 deficiency enhances the tumor phenotype of TCL1A (GFP 1 ) overexpressing B cells, as is shown by abnormal cell numbers and CD5 membrane expression level. (Upper left) B220 CD19 expression in gated GFP 1 cells expressing TCL1A in primary and secondary recipient mice engrafted with BM cells overexpressing TCL1A in a Tet2 1 / 1 or Tet2 2 / 2 background. (Lower left) Average 6 SD of the median fluorescence intensity of the B220 antigen at the cell surface of CD19 1 B cells in each group. (Upper right) Expression of CD5 and IgM on the gated B cells as in the upper-left contour plots. A representative contour plot is shown for each group. (Lower right)
Figure 5 Tet2 -deficient abnormal B-cells are BCR-inhibition sensitive. (A) Abnormal B-cell phenotype and frequencies in the peripheral blood of mice transplanted with TCL1A transduced Tet2 1 / 1 or Tet2 2 / 2 hematopoietic progenitors. Dot plots show a representative example of B220 and CD19 expression analysis in the GFP 1 total leukocytes 4 months after transplantation. Diagrams depict the average percentages of the B220 low population in the blood of n 5 3 mice per group 4 months after transplantation. Error bars represent means 6 standard deviation (SD). (B) Tet2 deficiency enhances the tumor phenotype of TCL1A (GFP 1 ) overexpressing B cells, as is shown by abnormal cell numbers and CD5 membrane expression level. (Upper left) B220 CD19 expression in gated GFP 1 cells expressing TCL1A in primary and secondary recipient mice engrafted with BM cells overexpressing TCL1A in a Tet2 1 / 1 or Tet2 2 / 2 background. (Lower left) Average 6 SD of the median fluorescence intensity of the B220 antigen at the cell surface of CD19 1 B cells in each group. (Upper right) Expression of CD5 and IgM on the gated B cells as in the upper-left contour plots. A representative contour plot is shown for each group. (Lower right)CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 38

  1. Muller-Sieburg, 2012, Stem cell heterogeneity: implications for aging and regenerative medicine, Blood, 119, 3900, 10.1182/blood-2011-12-376749 · DOI
  2. Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 · DOI · Paper page
  3. Langemeijer, 2009, Acquired mutations in TET2 are common in myelodysplastic syndromes, Nat Genet, 41, 838, 10.1038/ng.391 · DOI · Paper page
  4. Quivoron, 2011, TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis, Cancer Cell, 20, 25, 10.1016/j.ccr.2011.06.003 · DOI · Paper page
  5. Asmar, 2013, Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma, Haematologica, 98, 1912, 10.3324/haematol.2013.088740 · DOI
  6. Cimmino, 2015, TET1 is a tumor suppressor of hematopoietic malignancy, Nat Immunol, 16, 653, 10.1038/ni.3148 · DOI
  7. Haney, 2016, Loss of Dnmt3a induces CLL and PTCL with distinct methylomes and transcriptomes in mice, Sci Rep, 6, 34222, 10.1038/srep34222 · DOI
  8. Haney, 2016, Promoter hypomethylation and expression is conserved in mouse chronic lymphocytic leukemia induced by decreased or inactivated Dnmt3a, Cell Reports, 15, 1190, 10.1016/j.celrep.2016.04.004 · DOI
  9. Roos-Weil, 2016, Chronic lymphocytic leukemia: time to go past genomics?, Am J Hematol, 91, 518, 10.1002/ajh.24301 · DOI
  10. Chandra, 2015, AID targeting: old mysteries and new challenges, Trends Immunol, 36, 527, 10.1016/j.it.2015.07.003 · DOI
  11. Rickert, 1997, B lymphocyte-specific, Cre-mediated mutagenesis in mice, Nucleic Acids Res, 25, 1317, 10.1093/nar/25.6.1317 · DOI
  12. Muramatsu, 2000, Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme, Cell, 102, 553, 10.1016/S0092-8674(00)00078-7 · DOI
  13. Walter, 2010, Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency, J Exp Med, 207, 1541, 10.1084/jem.20091927 · DOI
  14. Ye, 2013, IgBLAST: an immunoglobulin variable domain sequence analysis tool, Nucleic Acids Res, 41, W34, 10.1093/nar/gkt382 · DOI
  15. Brochet, 2008, IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis, Nucleic Acids Res, 36, W503, 10.1093/nar/gkn316 · DOI
  16. Giudicelli, 2011, IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences, Cold Spring Harb Protoc, 2011, 695
  17. Lefranc, 2009, IMGT, the international ImMunoGeneTics information system, Nucleic Acids Res, 37, D1006, 10.1093/nar/gkn838 · DOI
  18. Damm, 2014, Acquired initiating mutations in early hematopoietic cells of CLL patients, Cancer Discov, 4, 1088, 10.1158/2159-8290.CD-14-0104 · DOI
  19. Stamatopoulos, 2007, Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations, Blood, 109, 259, 10.1182/blood-2006-03-012948 · DOI
  20. Yan, 2006, B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia, Proc Natl Acad Sci USA, 103, 11713, 10.1073/pnas.0604564103 · DOI · Paper page
  21. Hardy, 1991, Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow, J Exp Med, 173, 1213, 10.1084/jem.173.5.1213 · DOI
  22. Puente, 2011, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, 475, 101, 10.1038/nature10113 · DOI
  23. Zhang, 2013, Genetic heterogeneity of diffuse large B-cell lymphoma, Proc Natl Acad Sci USA, 110, 1398, 10.1073/pnas.1205299110 · DOI
  24. Pettersen, 2015, AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature, DNA Repair (Amst), 25, 60, 10.1016/j.dnarep.2014.11.006 · DOI
  25. Quesada, 2011, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat Genet, 44, 47, 10.1038/ng.1032 · DOI
  26. Schuh, 2012, Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns, Blood, 120, 4191, 10.1182/blood-2012-05-433540 · DOI
  27. Wang, 2011, SF3B1 and other novel cancer genes in chronic lymphocytic leukemia, N Engl J Med, 365, 2497, 10.1056/NEJMoa1109016 · DOI
  28. Lohr, 2012, Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing, Proc Natl Acad Sci USA, 109, 3879, 10.1073/pnas.1121343109 · DOI
  29. Morin, 2013, Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing, Blood, 122, 1256, 10.1182/blood-2013-02-483727 · DOI
  30. Pasqualucci, 2011, Analysis of the coding genome of diffuse large B-cell lymphoma, Nat Genet, 43, 830, 10.1038/ng.892 · DOI
  31. Pekarsky, 2015, The long journey of TCL1 transgenic mice: lessons learned in the last 15 years, Gene Expr, 16, 129, 10.3727/105221615X14181438356256 · DOI
  32. Bichi, 2002, Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression, Proc Natl Acad Sci USA, 99, 6955, 10.1073/pnas.102181599 · DOI · Paper page
  33. Benson, 2014, Modeling the clinical phenotype of BTK inhibition in the mature murine immune system, J Immunol, 193, 185, 10.4049/jimmunol.1302570 · DOI
  34. Casola, 2004, B cell receptor signal strength determines B cell fate, Nat Immunol, 5, 317, 10.1038/ni1036 · DOI
  35. Jeong, 2014, Large conserved domains of low DNA methylation maintained by Dnmt3a, Nat Genet, 46, 17, 10.1038/ng.2836 · DOI · Paper page
  36. Ko, 2015, TET proteins and 5-methylcytosine oxidation in hematological cancers, Immunol Rev, 263, 6, 10.1111/imr.12239 · DOI
  37. Wilson, 2015, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, Nat Med, 21, 922, 10.1038/nm.3884 · DOI
  38. Soucie, 2012, In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells, Blood, 120, 4846, 10.1182/blood-2011-12-397588 · DOI

Cited by

Metadata

Authors
Mouly, E., Ghamlouch, H., Della-Valle, V., Scourzic, L., Quivoron, C., Roos-Weil, D., Pawlikowska, P., Saada, V., Diop, M. K., Lopez, C. K., Fontenay, M., Dessen, P., Touw, I. P., Mercher, T., Aoufouchi, S., & Bernard, O. A.
Affiliations
  • INSERM, Unité Mixte de Recherche (UMR)1170, Institut Gustave Roussy, Villejuif, France;
  • Institut Gustave Roussy, Villejuif, France;
  • Département Développement, Reproduction, Cancer, Institut Cochin, INSERM U1016, CNRS UMR8104, Université Paris Descartes, Paris, France; and
  • Department of Hematology, Erasmus Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
ORCID
Ghamlouch, Hussein
Venue
Blood Advances
Publisher
American Society of Hematology
Published
2018-03-26
Volume
2
Issue
6
Pages
703-714
ISSN
  • 2473-9529
  • 2473-9537
DOI
10.1182/bloodadvances.2017014118
Cited by
58
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review